Skip to main content

sodium polystyrene sulfonate

Generic: SODIUM POLYSTYRENE SULFONATE·Brand: KALEXATE, KAYEXALATE, KIONEX, Kionex, SODIUM POLYSTYRENE SULFONATE, SPS

sodium polystyrene sulfonate: sourced relationships with 1 company · 2 FDA decisions.

sodium polystyrene sulfonate evidence translation

What we can confirm

What it means

Source-backed records connect sodium polystyrene sulfonate to ANIP; that link alone does not prove the drug works.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

How could sodium polystyrene sulfonate → ANIP affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

Dated Pipeline Records (1)
CompanyDated record stage
ANI PHARMACEUTICALS INC (ANIP)
Reported 2007-09-17 · Current development: unknownSource
Approved
FDA Decisions2 records
Approval1 INDICATIONS AND USAGE Sodium polystyrene sulfonate for suspension is indicated for the treatment of hyperkalemia. Limitation of Use : Sodium polystyrene sulfonate for suspension should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see Clinical Pharmacology (12.2) ] Sodium polystyrene sulfonate for suspension is a potassium binder indicated for the treatment of hyperkalemia ( 1 ). Limitation of Use : Sodium polystyrene sulfonate (ANIP)FDA ↗
ANDA090590OralSuspension
Approval(ANIP)FDA ↗
ANDA040028OralSuspension

Frequently asked questions

Which companies have sourced relationships with sodium polystyrene sulfonate?

sodium polystyrene sulfonate has dated SEC/FDA relationship records for ANI PHARMACEUTICALS INC.

What is sodium polystyrene sulfonate's latest FDA decision?

The most recent tracked FDA decision for sodium polystyrene sulfonate is Approval for 1 INDICATIONS AND USAGE Sodium polystyrene sulfonate for suspension is indicated for the treatment of hyperkalemia. Limitation of Use : Sodium polystyrene sulfonate for suspension should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see Clinical Pharmacology (12.2) ] Sodium polystyrene sulfonate for suspension is a potassium binder indicated for the treatment of hyperkalemia ( 1 ). Limitation of Use : Sodium polystyrene sulfonate , dated May 13, 2011.